Table 3. Monoclonal antibodies currently under evaluation for cancer therapy in phase III-IV trials*.
| mAb | Target | Type | Identifier | Phase | Indication(s) |
|---|---|---|---|---|---|
| Brentuximab vedotin** |
CD30 |
MMAE-conjugated C IgG1 |
NCT01100502 |
III |
Hodgkin lymphoma |
| Ch14.18 |
GD2 |
C IgG1 |
NCT01041638 |
III |
Neuroblastoma |
| Denosumab*** |
RANKL |
H IgG2 |
NCT01077154 |
III |
High risk early breast cancer receiving neoadjuvant or adjuvant therapy |
| Ganitumab |
IGF1R |
H IgG1 |
NCT01231347 |
III |
Metastatic adenocarcinoma of the pancreas |
| Necitumumab |
EGFR |
H IgG1 |
NCT00981058 |
III |
NSCLC |
|
NCT00982111 |
III |
NSCLC |
|||
| Nimotuzumab |
EGFR |
Hzed IgG1 |
NCT01074021 |
III |
Nasopharyngeal cancer |
|
NCT00957086 |
III |
HNC |
|||
|
NCT01249352 |
III |
Locally advanced esophageal cancer |
|||
|
NCT01402180 |
III |
Esophageal squamous cell carcinoma |
|||
| Ramucirumab |
VEGFR2 |
H IgG1 |
NCT00917384 |
III |
Metastatic gastric or gastresophageal junction adenocarcinoma. |
|
NCT01140347 |
III |
Hepatocellular carcinoma after 1st line therapy with sorafenib |
|||
| Siltuximab | IL-6 | C IgG1 | NCT01266811 | III | Relapsed or refractory multiple myeloma |
Abbreviations: C, chimeric; EGFR, epidermal growth factor receptor; H, human; HNC, head and neck cancer; Hzed, humanized; IGF1R, insulin-like growth factor 1 receptor; IL, interleukin; MMAE, monometil auristatin E; NSCLC, non-small cell lung cancer; RANKL, RANK ligand; VEGFR2, vascular endothelial growth factor receptor 2. *started after January, 1st 2008 and not completed or terminated at the day of submission; **currently reviewed by FDA and EMA; ***approved by both FDA and EMA for the therapy of bone loss during osteoporosis.